Epidemiology of venous thromboembolism in 9489 patients with malignant glioma
TJ Semrad, R O'Donnell, T Wun, H Chew… - Journal of …, 2007 - thejns.org
Object The authors sought to define the incidence of symptomatic venous thromboembolism
(VTE) in patients harboring malignant gliomas. Methods The authors conducted a …
(VTE) in patients harboring malignant gliomas. Methods The authors conducted a …
Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline
…, H Park, A Saeed, TJ Semrad… - Journal of Clinical …, 2023 - ingentaconnect.com
PURPOSE To develop recommendations involving targeted therapies for patients with
advanced gastroesophageal cancer. METHODS The American Society of Clinical Oncology …
advanced gastroesophageal cancer. METHODS The American Society of Clinical Oncology …
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).
…, SE Wang, CH Lieu, SG Eckhardt, TJ Semrad… - 2017 - ascopubs.org
520 Background: BRAF V600 mutations are associated with rare objective responses to the
mutated BRAF inhibitor vemurafenib in patients with mCRC. Blockade of BRAF V600 by …
mutated BRAF inhibitor vemurafenib in patients with mCRC. Blockade of BRAF V600 by …
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG …
RS Herbst, MW Redman, ES Kim, TJ Semrad… - The Lancet …, 2018 - thelancet.com
Background EGFR antibodies have shown promise in patients with advanced non-small-cell
lung cancer (NSCLC), particularly with squamous cell histology. We hypothesised that …
lung cancer (NSCLC), particularly with squamous cell histology. We hypothesised that …
Phase I trial of arginine deprivation therapy with ADI-PEG 20 plus docetaxel in patients with advanced malignant solid tumors
…, T Li, MP Dutia, K Kelly, IY Gong, T Semrad… - Clinical Cancer …, 2015 - AACR
Purpose: This phase I study examined the toxicity and tolerability of pegylated arginine
deiminase (ADI-PEG 20) in combination with docetaxel in patients with advanced solid …
deiminase (ADI-PEG 20) in combination with docetaxel in patients with advanced solid …
Role of treatment deintensification in the management of p16+ oropharyngeal cancer: ASCO provisional clinical opinion
…, CU Jones, M Kaufman, QT Le, TJ Semrad… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO’s
membership after publication or presentation of potentially practice-changing data from major …
membership after publication or presentation of potentially practice-changing data from major …
Fibroblast growth factor signaling in non–small-cell lung cancer
TJ Semrad, PC Mack - Clinical lung cancer, 2012 - Elsevier
Despite recent progress in the treatment on non–small cell lung cancer (NSCLC), outcomes
remain suboptimal. Treatment advances that target the epidermal growth factor receptor (…
remain suboptimal. Treatment advances that target the epidermal growth factor receptor (…
Geographic variation of racial/ethnic disparities in colorectal cancer testing among Medicare enrollees
TJ Semrad, DJ Tancredi, LM Baldwin, P Green… - Cancer, 2011 - Wiley Online Library
BACKGROUND: The Medicare population has documented racial/ethnic disparities in
colorectal cancer (CRC) screening, but it is unknown whether these disparities differ across …
colorectal cancer (CRC) screening, but it is unknown whether these disparities differ across …
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors
…, J Strosberg, TJ Hobday, T Semrad… - Endocrine-related …, 2023 - erc.bioscientifica.com
We assessed the efficacy and safety of combining bevacizumab with temsirolimus in patients
with advanced extra-pancreatic neuroendocrine tumors. This NCI-sponsored multicenter, …
with advanced extra-pancreatic neuroendocrine tumors. This NCI-sponsored multicenter, …
Oxaliplatin–DNA adducts as predictive biomarkers of FOLFOX response in colorectal cancer: A potential treatment optimization strategy
FOLFOX is one of the most effective treatments for advanced colorectal cancer. However,
cumulative oxaliplatin neurotoxicity often results in halting the therapy. Oxaliplatin functions …
cumulative oxaliplatin neurotoxicity often results in halting the therapy. Oxaliplatin functions …